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Abstract: Inflammatory bowel disease (IBD) is characterized by chronic inflammation of the intestine
that compromises the patients’ life quality and requires sustained pharmacological and surgical
treatments. Since their etiology is not completely understood, non-fully-efficient drugs have been
developed and those that have shown effectiveness are not devoid of quite important adverse
effects that impair their long-term use. In this regard, a growing body of evidence confirms the
health benefits of flavonoids. Flavonoids are compounds with low molecular weight that are
widely distributed throughout the vegetable kingdom, including in edible plants. They may be
of great utility in conditions of acute or chronic intestinal inflammation through different mechanisms
including protection against oxidative stress, and preservation of epithelial barrier function and
immunomodulatory properties in the gut. In this review we have revised the main flavonoid
classes that have been assessed in different experimental models of colitis as well as the proposed
mechanisms that support their beneficial effects.
Keywords: inflammatory bowel disease; flavonoids; oxidative stress; eicosanoids; barrier function;
immunomodulatory properties
1. Introduction
Inflammatory bowel disease (IBD) mainly comprises two major conditions, Crohn’s disease (CD)
and ulcerative colitis (UC), characterized by chronic gastrointestinal inflammation with alternating
periods of relapses and remissions. Both forms of IBD are featured by exacerbated uncontrolled
intestinal inflammation that leads to poor quality of life and requires prolonged medical and/or
surgical interventions. Histologically, the examination of intestinal tissue from patients with active
disease shows inflammatory cell infiltration corresponding with dramatic tissue injury including
edema, loss of goblet cells, fibrosis, erosions and ulcers. In CD patients, the inflammation can
intermittently affect any part of the gastrointestinal tract, from the mouth to the anus, but it is
usually, although not always, localized in the distal small bowel and/or colon. The inflamed bowel
obtained from these patients with active CD reveals transmural inflammation characterized by the
presence of large numbers of acute and chronic inflammatory cells within the mucosa, submucosa
and muscularis propria [1]. However, UC patients exhibit a non-transmural inflammation, which is
restricted, exclusively, to the large bowel and rectum [2]. Typically, the inflammatory changes are
limited to the mucosa and submucosa with cryptitis and crypt abscesses, and the inflammatory cell
composition is similar to CD. The symptoms associated with both intestinal conditions are largely
dependent on disease location and can include diarrhea, abdominal pain, fever, clinical signs of bowel
obstruction, as well as passage of blood or mucus or both [1].
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At present, the etiology of IBD is not fully understood, and many theories have been proposed
to explain IBD pathogenesis, ranging from infectious to psychosomatic, social, metabolic, vascular,
genetic, allergic, autoimmune and immune-mediated mechanisms [3–5]. Currently, there is a general
agreement that IBD occurs in genetically predisposed subjects who exhibit a dysfunctional intestinal
epithelium barrier with increased tight junction permeability. In these conditions, these patients
develop an exaggerated immune response in the gut towards the intestinal microbiota, which is not
conveniently controlled and leads to chronic intestinal inflammation [3]. In fact, various components of
the mucosal immune system in the gut have been implicated in the pathogenesis of IBD. They include
elements of the innate immune system such as intestinal epithelial cells, macrophages/monocytes,
neutrophils, dendritic cells (DCs), as well as constituents of the adaptive immune system such as
T-cells and B-cells as well as their secreted mediators (cytokines and chemokines) (Figure 1). It has
been proposed that an initial defect in sampling gut luminal antigens, or a mucosal susceptibility,
leads to the activation of the innate immune response, most probably associated with an enhanced
Toll-like Receptor (TLR) activity. Then, antigen-presenting cells (APCs) can mediate the differentiation
of naïve T-cells into effector T helper (Th) cells, including Th1, Th2, and Th17 cell types, and
macrophage proliferation, thus impairing the immune tolerance to commensal bacteria in the
intestine [6]. In consequence, there is an abnormal synthesis and release of different pro-inflammatory
mediators, including eicosanoids, platelet-activating factor, cytokines and reactive oxygen and nitrogen
metabolites, which lead to the mucosal damage and the generation of a vicious circle that sustains the
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Figure  1.  The mucosal  immune  system  constitutes  a  key  element  in  preventing  penetration  of 
microorganisms. It consists of innate and adaptive immune responses. The innate immune response 
is  the  first  line  of  defense  against  infection  and  includes  complement  proteins,  granulocytes 
(basophils, eosinophils and neutrophils), mast cells, macrophages, dendritic cells and natural killer 
cells.  The  adaptive  immune  response  develops  more  slowly,  but  it  is  manifested  as  increased 
antigenic  specificity  and  memory.  It  consists  of  antibodies,  B  cells,  and  CD4+  and  CD8+  T 
lymphocytes.  Disruption  of  the  innate  and  acquired  gut  immune  systems  may  cause  the 
development of chronic intestinal diseases. 
Figure 1. The ucosal i une syste constitutes a key ele ent in preventing penetration of
icroorganis s. It consists of innate and adaptive immune responses. The innate im une response is
the first line of defense against infection and includes complement proteins, granulocytes (basophils,
eosinophils and neutrophils), mast cells, acrophages, dendritic cells and natural killer cells. The
adaptive immune response develo s more slowly, but it is manifested as increased antigenic specificity
d memory. It consists of antibodies, B cells, and CD4+ and CD8+ T lymphocytes. Disruption of the
innate and acquired gut immune systems m y cause the evelopment of chronic intestinal diseases.
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Nowadays, and since the precise etiology of IBD is unknown, there is no specific causal treatment
for these intestinal conditions. For this reason, the main goals of IBD therapy are, firstly, to induce the
remission of the symptoms during the acute flare, and secondly, to preserve the remission by controlling
the chronic inflammation, thus preventing the reactivation of the intestinal inflammatory process.
With these aims, one of the main strategies to effectively counteract the exacerbated immune response
is to interfere with multiple stages of the inflammatory cascade, mainly by using aminosalicylates
(sulfasalazine or mesalazine), immunosuppressants (glucocorticoids, azathioprine, methotrexate, and
cyclosporine A), and biologicals (infliximab or adalimumab) [10]. Unfortunately, these treatments are
not devoid of potentially serious side effects, thus limiting their chronic use [11]. In consequence, there
is a clear demand for safe and effective therapeutic strategies for human IBD. This could be the case for
flavonoids, natural phenolic products that are found in edible fruit and vegetables and present several
biological activities, mainly related to their antioxidant properties and ability to inhibit enzymes, which
justify their reported capacity to downregulate the immune response [12]. Therefore, they could be
taken into consideration as potential drugs for the pharmacological treatment of IBD. The aim of this
review is to provide scientific arguments that would support the use of flavonoids in the treatment of
human IBD, based on different studies that have shown the efficacy of these compounds both in clinical
trials and in an experimental model of rodent colitis. Moreover, we will analyze the mechanisms
that may be involved in their beneficial effects in these intestinal conditions. With this purpose we
will focus on the most relevant groups of flavonoids with demonstrated intestinal anti-inflammatory
properties: anthocyanidins, catechins, chalcones, flavanones, flavones, flavonols, isoflavones.
2. The Inflammatory Response in the Gut: Cellular and Molecular Mechanisms
The gastrointestinal tract is key for the maintenance of immune homoeostasis, and any
dysregulation could result in different pathologies, including IBD. The intestinal innate immune
system is the first line of defense, thus providing an immediate protective response against infections,
and it also helps to initiate the adaptive immune response. The innate immune system comprises the
epithelial cell barrier, macrophages, monocytes, neutrophils, DCs, natural killer (NK) cells, eosinophils
and basophils. These cells act together to confer tolerance or to initiate inflammation by secreting
cytokines, chemokines and antimicrobial agents. Besides, the surface of the intestine is protected by a
layer of mucus that is generated by the goblet cells of the epithelium.
It has been proposed that one of the early steps that occur in IBD is related to the disruption of the
epithelial-cell barrier that may result in inflammation and dysregulation of the mucosal homeostasis.
In this setting, some of the cells involved in innate immunity, such as macrophages and DCs, are able to
identify microorganisms’ molecular patterns by using the corresponding pattern recognition receptors
(PRR), including TLRs [13]. This promotes the recruitment of monocyte-derived macrophages that
generate cytokines and chemokines to attract monocytes and other leukocyte populations in an attempt
to contain the inflammation [14]. When innate immunity fails to counteract the pathogen aggression,
the adaptive immune response is triggered. In this process, DCs get into the mesenteric lymph nodes,
and then they present the antigen to naive T cells and, depending on the factors released by DCs,
induce the T cell differentiation [15]. T cells are the key players of the adaptive immune response,
and in collaboration with other cells and molecules from the innate immune system, are able to
trigger an effective response to remove the invading pathogens. Depending on the effector cytokines
produced by APCs, naive T cells have the potential to differentiate into different T helper (Th) subtypes.
IL-12 generates Th1 cells, IL-4 promotes Th2 differentiation, IL-10 and TGF-β induce regulatory
T cells (iTreg), whereas IL-6, IL-1β and TGF-β promote Th17 cells [16–19]. It has been reported that
these Th subtypes exhibit specific functions; whereas Th1 cells are crucial for removing intracellular
pathogens, Th2 cells mediate allergic reactions and protect against parasites, and Th17 cells contribute
to eliminating extracellular bacteria and fungi [20,21]. In addition to Th cells, neutrophils are also
able to infiltrate the inflamed mucosa. These activated leukocytes generate several pro-inflammatory
cytokines, but they also play a key role in inducing oxidative reactions, thus modifying the redox
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balance in the gut mucosa, which can collaborate to maintain the inflammatory status through the
upregulation of redox-sensitive signaling pathways and transcription factors [22]. Furthermore, all the
inflammatory molecules involved in these intestinal conditions produce additional oxidation products,
thus resulting in a self-sustaining and auto-amplifying vicious circle, which ultimately worsens
the already-compromised gut barrier integrity. Accordingly, and similarly to other inflammatory
disorders, the complex immune cell response in IBD implies the participation of an extensive variety
of inflammatory mediators, including cytokines, chemokines, leukotrienes and prostaglandins. All of
them contribute actively to the inflammatory process at different stages: initiation, progression and
resolution, if it happens.
It is well reported that there is increased expression of chemokines in the active phases of
IBD, including IL-8, monocyte chemoattractant protein (MCP)-1 and MCP-3, and macrophage
inflammatory proteins (MIP), which are responsible for the recruitment of different leukocyte
effector populations, by controlling their adhesion and migration across the endothelium in sites
of inflammation. Moreover, these mediators are also able to trigger other inflammatory processes such
as leukocyte activation, granule exocytosis, activation of metalloproteinases for matrix degradation
and upregulation of the oxidative burst, which are actively involved in the tissue injury that occurs
in intestinal inflammation [23]. Likewise, there is upregulated expression and release of different
adhesion molecules in IBD, such as the intercellular adhesion molecule (ICAM)-1, the lymphocyte
function-associated antigen (LFA)-1, the macrophage 1 antigen (Mac-1), the vascular cell adhesion
molecule (VCAM)-1, the very late antigen (VLA)-4 and P- and E-selectins, which also participate in the
recruitment of leukocytes to the inflamed tissue [24].
When considering the cytokines, their roles in IBD are very diverse and complex, and they have a
key role in controlling T-cell differentiation and regulation. Thus, they are considered as crucial targets
to control the inflammatory response. IL-12, IL-18 and IL-23 are responsible for Th1 differentiation and
chronic activation, whereas other cytokines, such as TNFα, IL-1β and IL-6, enhance the inflammatory
response by promoting the recruitment and activation of other inflammatory elements, thus increasing
the production and release of inflammatory mediators [25]. Additionally, the activation of PRRs
induces the expression of IL-23, which enhances both Th1 and Th17 responses, this being associated
with an increased production of other cytokines such as IFNγ, IL-17 and IL-22 in chronic intestinal
inflammation [26,27]. The IL-17 cytokine family comprises a group of at least six members, IL-17A,
IL-17B, IL-17C, IL-17D, IL-17E, (or IL25) and IL17F, which have been reported to display potent
pro-inflammatory responses both in vitro and in vivo [28]. In fact, IL-17 increases the expression
of pro-inflammatory cytokines, including IL6 and TNFα, chemokines, such as the keratinocyte
chemoattractant (KC), MCP-1 and MIP-2, and matrix metalloproteases, all of them involved in tissue
infiltration and tissue damage [29], and thus revealing a crucial function in the pathogenesis of human
IBD [30]. Finally, it is important to note that an altered production of anti-inflammatory cytokines, such
as IL-10 and TGFβ, can also contribute to the pathogenesis of IBD, given the key role attributed to these
cytokines as regulators of intestinal immune homeostasis and the inflammatory responses [31,32].
3. Intestinal Anti-Inflammatory Effects of Flavonoids: In Vivo and in Vitro Studies
The biological activities ascribed to flavonoids, including antioxidant properties and the inhibition
of enzymatic activities, can justify the fact that many flavonoids have been described to suppress
inflammation, both in vivo and in vitro, thus reducing the severity of different inflammatory diseases,
including IBD [33,34]. Galsanov et al. (1976) reported for the first time the potential beneficial effect
of flavonoids in intestinal inflammation. In that study, the authors described the anti-inflammatory
activity of quercitrin, when administered at doses of 25 and 100 mg/kg, in a rat model of allergic
intestinal inflammation. Since then, many studies describing the impact of flavonoids in several
experimental models of colitis in rodents have been published. Among these, chemically induced
models (acetic acid, trinitrobenzenesulfonic acid (TNBS) or dextran sulphate sodium (DSS)), genetically
engineered mice (HLA-B27 rats or IL-10 knock-out (KO) mice), and a T cell–transfer model have been
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used broadly and have been shown to share some similarities with human IBD [35]. These studies have
revealed the intestinal anti-inflammatory activity of different flavonoids, including both glycosides and
aglycones, and those belonging to the different chemical classes, such as flavonols (quercetin, quercitrin,
rutin), flavanones (naringenin), flavones (baicalin, chrysin), catechins (epigallocatechin-3-gallate
(EGCG)), isoflavones (genistein, daidzein, glabridin), anthocyanidins (cyanidin-3-glucoside (C3G)),
and chalcones (cardamonin) (Table 1) (Figure 2). These beneficial effects were evidenced at acute and
semi-chronic stages of intestinal inflammation, following either a preventative dosing protocol, i.e.,
when administered before colitis induction or a curative administration of the test compounds once
the colonic damage had been developed. At present, it is difficult to establish a structure-activity
relationship, since the number of flavonoids tested until now is low. However, of all the flavonoids
tested, quercitrin has been found to be the most potent, showing preventative or curative properties
at doses of 1 and 5 mg/kg [36]. The range of active doses for the other flavonoids is broad, ranging
from 10 to 25 mg/kg when the glycosides are considered, and between 10 and 200 mg/kg in the case
of aglycones.
Table 1. Flavonoids’ intestinal anti-inflammatory effects.
Chemical Class Plant Source Mechanism References
Anthocyanins
Cyanidin-3-glucoside Hibiscus sabdariffaHibiscus sabdariffa
Inhibition PGE2 release by regulating COX-2 activity.
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Improvement epithelial barrier function. [42]




Inhibition reactive nitrogen species generation. [39]
Reduction pro-inflammatory mediators. [44]
Inhibition NF-κB activity.
Baicalin Scutellaria baicalensis
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Flavonols
Quercetin Dysosma veitchii
Inhibition reactive nitrogen species generation.




Inhibition leukocyte migration. [48]
Reduction pro-inflammatory mediators. [49]
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Reduction pro-inflammatory mediator production. [34]
Inhibition NF-κB activity.
Improvement epithelial barrier function.
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Figure 2. Chemical structures of the main flavonoids with intestinal anti-inflammatory properties.
At present, it is not completely clear whether these beneficial effects are due to a local action of
the flavonoid on the inflamed colonic tissue or whether they are derived from a systemic effect after
their absorption in the small intestine and subsequent metabolism, or both. For instance, regarding the
flavonol quercetin, the oral administration of its aglycone, at doses of 9 mg/kg [38], is devoid of any
beneficial effect, whereas its derived glycoside, quercitrin, shows intestinal anti-inflammatory effects
in different models of experimental colitis at doses under 5 mg/kg [36,39]. The aglycones are absorbed
in the small intestine while most glycosides reach the colon, where they are cleaved by the microbiota
and the moiety of the aglycone is released. This could explain why the glycoside derivatives could be
more potent on colonic inflammation when they are administered orally.
The flavonoid treatments have shown beneficial effects that were evidenced macroscopically
by the amelioration of colonic damage. In the DSS model, characterized by intense colonic damage
associated with inflammatory cell infiltration and epithelial crypt loss, which results in acute clinical
symptoms including body weight loss, bloody stools and diarrhea, the treatment with some flavonoids
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such as cardamonin, chrysin, naringenin, EGCG, glabridin, rutin and quercitrin significantly reduced
the Disease Activity Index (DAI), which is used to monitor the severity of the inflammatory process,
as well as the colon shortening. Therefore, DSS-induced weight loss and histological damage were
significantly ameliorated by flavonoid treatment [40,50,55–60]. In line with this finding, it has been
shown that quercitrin and rutin administration was able to decrease colonic damage, reducing the
length of the injury and attenuating the diarrhea symptoms in the TNBS model [61,62]. Moreover,
rutin also ameliorated histologic injury in the acetic acid model of experimental colitis [63].
The involvement of different mechanisms in the intestinal anti-inflammatory activity of the
flavonoids has been proposed, including antioxidant properties through interference with reactive
oxygen (ROS) and nitrogen (RNS) species, inhibition of eicosanoid synthesis, immunomodulatory
activity, preservation of the epithelial barrier function and, finally, an interference with the
gut microbiota.
3.1. Antioxidant Properties of Flavonoids
Several studies have proposed that both ROS and RNS also play a key role in the etiology of
IBD [64]. In fact, human IBD has been associated with an intense oxidative stress, excessive generation
of ROS and RNS in the intestinal tissue which induces lipid peroxidation, protein modifications, DNA
damage, and apoptosis, together with impairment of the enzymatic and non-enzymatic antioxidant
mechanisms, including superoxide dismutase (SOD), and reduced glutathione (GSH) and catalase
(CAT), which results in the colonic damage associated with intestinal inflammation [22,65]. Different
sources of free radicals have been proposed to contribute to the oxidative burst that takes place
in IBD, with neutrophils among the cells most involved in these processes [54]. The infiltration
of polymorphonuclear neutrophils and mononuclear cells into the affected part of the intestine is
considered one of the main pathological features of human IBD [66]. As a consequence of the activation
of the nicotinamide adenine dinucleotide phosphate (NADPH) oxidase system in these cells, and
the subsequent myeloperoxidase activity (MPO), massive quantities of superoxide and hypochlorous
acid are generated and cause direct cytotoxicity in the intestinal tissue. This, in turn, facilitates the
additional release of different pro-inflammatory mediators [48]. In fact, most flavonoids assayed
in experimental colitis models exhibited a significant reduction of colonic myeloperoxidase. This
enzyme is predominantly found in the azurophilic granules of the neutrophils and is considered
to be a sensitive marker of leukocyte infiltration [67]. As expected, MPO activity is increased in
different experimental models of colitis induced by TNBS, DSS and T cell transfer. The increased MPO
levels were significantly reduced after the administration of genistein and quercitrin in the TNBS
model [61,68]. A similar effect was induced by quercitrin as well as with cardamonin, chrysin, EGCG,
naringenin and rutin in the DSS model [40,50,55–57,60,69]. Finally, it is important to remark that rutin
administration was also able to reduce leukocyte infiltration in the T cell transfer model [70].
Most of the flavonoids assayed were able to ameliorate the oxidative stress that takes place in
the experimental models of colitis as evidenced by a reduced colonic lipid peroxidation, together
with an improvement in different antioxidant markers, including sulfhydryl-derived compounds, or
an enhancement of different enzyme activities with antioxidant properties [69]. Specifically, several
studies have suggested that both EGCG and quercitrin administration on the DSS-induced colitis
model were able to increase the colonic GSH production, and naringenin and EGCG reduced the tissue
malondialdehyde (MDA) levels, indicating both a reduction of lipid peroxidation and an increase of
antioxidant enzymes such as SOD and GPO [55,56,60,71]. Similarly, quercitrin and rutin treatment
have shown to significantly increase GSH levels, thus ameliorating the colonic damage in the TNBS
model [61].
Special attention can be paid to the RNS, which can be produced and released by immune cells and
also play an important role in the pathophysiology of IBD. Nitric oxide (NO) is a pleiotropic free radical
messenger molecule produced from L-arginine by the nitric oxide synthase (NOS) enzyme. Under
physiological conditions, low levels of NO are produced by the isoform of constitutive nitric oxide
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synthase (cNOS), which has a direct protective effect throughout the initial phases of the intestinal
inflammatory process. Nevertheless, in chronic inflammation, NO synthesis is upregulated, mainly as a
consequence of the increased expression of the inducible isoform of nitric oxide synthase (iNOS), which
is induced, mainly in macrophages, by bacterial products and pro-inflammatory cytokines [47,72]. The
overproduction of NO contributes to colonic damage due to its interaction with the superoxide anions,
thus generating peroxynitrites, which reinforce oxidative stress and tissue damage [41] (Figure 3).
Numerous studies have described an effect of flavonoids on the metabolism of NO, which may
preserve the beneficial functions of NO through the direct capture of super oxide anions [73]. Similarly,
it has been reported that flavonoids are capable of inhibiting the expression of iNOS [60] as well as
acting as powerful captors of peroxinitrite radicals [74]. Moreover, DSS administration is associated
with a significant increase of iNOS. In this regard, it has been observed that some flavonoids such
as glabridin, cardamonin, naringenin and quercitrin improve the inflammatory process, reducing
the expression of iNOS and, as a consequence, the NO production [40,58–60]. These results have
been confirmed in in vitro studies with different cell lines. EGCG, naringenin, daidzenin, kaempferol,
quercetin and cardamonin inhibit iNOS protein and mRNA expression and also NO production
in lipopolysaccharide (LPS)-activated macrophages, such as bone marrow–derived macrophages
(BMDM), or murine macrophages J774 and mouse leukemic monocyte macrophage (RAW 264.7) cell
lines [39,40,71,75]. Flavonoids are capable, therefore, of preventing the detrimental effects generated
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3.2. Effects of Flavonoids on Eicosanoid Metabolism and Function
Eicosanoids derived from arachidonic acid metabolism, including products from cyclooxygenase
(COX) (prostaglandins) and lipoxygenase (LOX) (leukotrienes), seem to also play a critical role in
intestinal inflammation. In fact, it has been demonstrated that increased levels of eicosanoids are
found in the inflamed tissue areas in comparison with normal mucosa in human IBD [76]. Actually,
the upregulation of the enzymes involved in the eicosanoid metabolism has also been associated with
the pathophysiology of other inflammatory disorders [77].
There are two isoforms of COX: constitutive COX-1 and inducible COX-2. COX-1 has been
considered crucial for mucosal integrity since it produces cytoprotective and anti-inflammatory
prostaglandins such as PGE2 [37]. On the contrary, the expression of COX-2 can be induced by
a variety of stimuli related to the inflammatory response. This isoform is responsible for an increased
production of prostaglandins involved in IBD [78,79] (Figure 4). In consequence, and theoretically,
the inhibition of COX-2 expression and/or activity would be also beneficial in the management of
intestinal inflammation. Different studies have reported that the intestinal anti-inflammatory activity
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Figure  4. Eicosanoid  synthesis pathways: Arachidonic acid  is a polyunsaturated  fatty acid  that  is 
released from the cellular membranes by cytoplasmatic phospholipase A2 (PLA2). Free arachidonic 
acid can be metabolized to eicosanoids through two major pathways: the cyclooxygenase (COX) and 
the  lipooxygenase  (LOX).  The  COX‐1  (constitutive  form)  pathway  results  in  the  synthesis  of 
prostaglandins  and  thromboxanes, which  are  important  for  physiological  functions.  The  COX‐2 
(inducible  form)  pathway  plays  a  crucial  rule  in  the  production  and  release  of  inflammatory 
prostaglandins.  Similarly,  the  LOX  pathway  leads  to  the  synthesis  of  leukotrienes  and 
hydroxyeicosatetraenoic acid (HETE) that contribute to the inflammatory process. Different studies 
have associated the flavonoid anti‐inflammatory effect with a suppression of these pathways. 
Interestingly,  it was  reported  that  C3G  has  inhibitory  effects  on  the  production  of  several 
mediators  during  inflammation  in  the  colonic  carcinoma  cell  line  HT29,  in  comparison  with 
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treatment with 25 mM C3G, 500 mM 5‐ASA or both, for one hour, before cytokine (IL‐1α, TNFα and 
IFNα)  stimulation,  significantly  reduced PG2 production. C3G produced  the  strongest  inhibition 
(65%)  while  5‐ASA  produced  a  significantly  lower  inhibition  (50%).  Additionally,  C3G 
downregulated COX‐2 expression more efficiently  than 5‐ASA, and  the  combination of C3G and 
5‐ASA afforded a much better protection than that of the individual compounds [80]. 
On  the  other  hand,  the  increased  generation  of  leukotrienes,  mainly  LTB4,  has  also  been 
reported  to occur  in  IBD  [81].  In  this  regard,  it has been proposed  that  leukotrienes mediate  the 
intestinal  inflammatory  response,  especially  through  their  chemotactic  effects,  thus  inducing  the 
accumulation of inflammatory cells in the inflamed area of the gut. In consequence, the inhibition of 
lipoxygenase  activity  and  the  subsequent  reduction  of  LTB4  production,  or  the  blockade  of  its 
receptor,  could  be  proposed  to  exert  beneficial  effects  in  experimental  colitis  [46,82]. However, 
although  different  flavonoids with  beneficial  effects  in  experimental  colitis were  able  to  reduce 
Figure 4. Eicosanoid synthesis path ays: Arachidonic acid is a polyunsaturated fatty acid that is
released fro the cellular membranes by cytoplasmatic phospholipase A2 (PLA2). Free arachidonic acid
can be metabolized to eicosanoids through two major pathways: the cyclooxygenase (COX) and the
lipooxygenase (LOX). The COX-1 (constitutive form) pathway results in the synthesis of prostaglandins
and thromboxanes, which are important for physiological functions. The COX-2 (inducible form)
pathway plays a crucial rule in the production and release of inflammatory prostaglandins. Similarly,
the LOX pathway leads to the synthesis of leukotrienes and hydroxyeicosatetraenoic acid (HETE)
that contribute to the inflammatory process. Different studies have associated the flavonoid
anti-inflammatory effect with a suppression of these pathways.
i l , it was reported tha C3G has inhibitory effects on the production of several mediators
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(5-ASA), a well-established anti-inflammatory drug used in IBD. In this regard, treatment with 25 mM
C3G, 500 mM 5-ASA or both, for one hour, before cytokine (IL-1α, TNFα and IFNα) stimulation,
significantly reduced PG2 production. C3G produced the strongest inhibition (65%) while 5-ASA
produced a significantly lower inhibition (50%). Additionally, C3G downregulated COX-2 expression
more efficiently than 5-ASA, and the combination of C3G and 5-ASA afforded a much better protection
than that of the individual compounds [80].
On the other hand, the increased generation of leukotrienes, mainly LTB4, has also been reported
to occur in IBD [81]. In this regard, it has been proposed that leukotrienes mediate the intestinal
inflammatory response, especially through their chemotactic effects, thus inducing the accumulation
of inflammatory cells in the inflamed area of the gut. In consequence, the inhibition of lipoxygenase
activity and the subsequent reduction of LTB4 production, or the blockade of its receptor, could
be proposed to exert beneficial effects in experimental colitis [46,82]. However, although different
flavonoids with beneficial effects in experimental colitis were able to reduce colonic LTB4 production,
no direct relationship between the reduced levels of this eicosanoid in the colonic tissue and the
anti-inflammatory effect can be established [36,53].
3.3. Immunomodulatory Properties of Flavonoids
As mentioned previously, most of the studies performed in experimental models of colitis have
proposed that an imbalance of the immune system plays a key role in IBD pathogenesis. The altered
immune response is associated with an increased release of pro-inflammatory cytokines, including
IFNγ, TNFα, IL-6, IL-1β, GM-CSF and IL-17A, chemokines, such as IL-8, MIP-2 and MCP-1, and
adhesion molecules, such as ICAM-1. The ability of flavonoids to regulate the altered immune response
that occurs in intestinal inflammation has been reported in different in vivo studies. For instance, the
administration of flavonoids, such as EGCG, cardamonin, chrysin, glabridin, quercitrin, naringenin or
rutin, in the DSS model remarkably decreased the increased levels of the different cytokines evaluated
in the inflamed colon [40,44,55–60].
These immunomodulatory properties exerted by the flavonoids have also been confirmed
when in vitro experiments were performed in different cell types involved in the immune response:
epithelial cells, monocytes/macrophages, T cells, and dendritic cells. For instance, the incubation
of LPS-activated macrophages, RAW 264.7 and BMDM cells with quercetin or baicalin resulted
in reduced levels of IL-1β and TNFα when compared with stimulated cells without flavonoid
treatment [39,83]. Similarly, rutin was able to significantly reduce increased IL-1β levels produced by
DSS-stimulated pMϕ cells, obtained from mouse peritoneal exudate [58,84]. In addition, quercetin
exerts anti-proliferative effects by reducing IFNγ and TNFα production in concavalin A-stimulated
purified T lymphocytes isolated from rat splenocytes [70]. Moreover, the incubation of flavonoids, such
as C3G, genistein, EGCG or chrysin, in cytokine-stimulated epithelial cells, Caco-2 and HT-29 cells
significantly reduces IL-8 secretion in the cell culture [80,85]. Finally, it has been shown that treatment
of THP-1 cells, a human monocytic cell line, with EGCG decreased MCP-1 and CCR2 gene expression,
together with MCP-1 secretion and CCR2 expression, at the cell surface, and induced the inhibition of
beta1 integrin activation [45].
Considering the role of immune cells in the development of IBD, T cells are major players [86].
Likewise, DSS-induced experimental colitis has been associated with an increased percentage of
Th1 and Th17 cells in the mesenteric lymph nodes, which correlates to the overexpression of
pro-inflammatory cytokines such as IFNγ, IL-17A and IL-17F. In this regard, it has been reported that
the beneficial effects observed with the flavonoid derivative icariin in DSS-induced colitis in mice
were related to a downregulation of the proportion of both Th1 and Th17 cells, and thus a reduction
in the cytokine release by these cell subtypes in the colonic tissue [87]. Different in vitro studies
have also confirmed the ability of flavonoids to suppress T cell proliferation and activation [87–89].
Moreover, baicalin was able to reduce the expression of RORC, Foxp3 and T-bet, transcription factors
associated with Th17, Treg and Th1 cells, respectively, which have been reported to be upregulated
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in UC patients [90]. Similarly, macrophages have been considered to be the main source of different
pro-inflammatory mediators in IBD, including TNFα, IL-1β and NO, thus actively contributing to the
pathology of these intestinal conditions [91,92]. Besides, several in vitro studies have shown the capacity
of flavonoids to inhibit NO and cytokine production in different macrophage cell lines, including RAW
264.7 and J774.1, as well as in bone marrow–derived macrophages (BMDM) [33,93]. In vivo experiments
have also revealed that the beneficial intestinal anti-inflammatory effects of flavonoids, such as
quercitrin, were associated with a decreased number of infiltrated macrophages in the inflamed colonic
tissue induced by DSS in rats [60]. Finally, and as mentioned above, neutrophil infiltration can be
considered one of the main pathological features of human IBD [66], and most active flavonoids assayed
in experimental colitis models significantly reduced neutrophil infiltration into the damaged colonic
tissue, as evidenced by a significant reduction of colonic myeloperoxidase [40,50,55–57,60,61,68–70],
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Figure  5. NF‐kB  signal  transduction  pathway. NF‐κB  protein  complex  (p65–p50)  is  bound  and 
inhibited by  IκB proteins. Pro‐inflammatory cytokines, LPS, growth  factors, and antigen receptors 
activate  an  IKK  complex  (IKKβ,  IKKα,  and  IKKγ),  which  phosphorylates  IκB  proteins. 
Phosphorylation of  IκB  leads  to  its ubiquitination and proteasomal degradation,  releasing NF‐κB. 
Active NF‐κB proteins  are  further  activated by post‐translational modifications  (phosphorylation, 
acetylation, glycosylation) and translocate to the nucleus where they induce target gene expression, 
influencing  a  broad  range  of  biological  processes  including  innate  and  adaptive  immunity, 
Figure 5. NF-kB signal transduction pathway. NF-κB protein complex (p65–p50) is bound and inhibited
by IκB proteins. Pro-inflammatory cytokines, LPS, growth factors, and antigen receptors activate an
IKK complex (IKKβ, IKKα, and IKKγ), which phosphorylates IκB proteins. Phosphorylation of IκB
leads to its ubiquitination and proteasomal degradation, releasing NF-κB. Active NF-κB proteins are
further activated by post-translational modifications (phosphorylation, acetylation, glycosylation) and
translocate to the nucleus where they induce target gene expression, influencing a broad range of
biological processes including innate and adaptive immunity, inflammation, stress responses, B cell
development, and lymphoid organogenesis. Anti-inflammatory effects of several flavonoids have been
related to the suppression of the NF-κB signal transduction pathway.
Several studies have focused on the potential mechanisms responsible for the modulation of
cytokine production; some of the mechanisms proposed are related to the inhibition of nuclear factor-κB
(NF-κB), mitogen-activated protein kinase (MAPK) and STAT activation [94–97]. NF-κB is ubiquitously
expressed, being found in its inactive form in the cytoplasm, which is bound to its high-affinity
inhibitor IκB. In the presence of an activating stimulus, including oxidative stress, a large signaling
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cascade is initiated, resulting in the activation of IKK-α and IKK-β, two kinases that phosphorylate IκB.
Phosphorylation of IκB results in its dissociation, and NF-κB becomes free to translocate to the nucleus,
where it binds to κB regulatory elements, activating gene expression [98] (Figure 5). It has been clearly
demonstrated that cardamonin and quercitrin exerted potent anti-inflammatory properties by reducing
NF-κB activity in DSS-induced experimental colitis, whereas rutin reduced IκBα phosphorylation in
a T cell transfer model [51,60,70]. Baicalin has also shown the ability to block this pathway in the
TNBS model of rat colitis [83]. In this regard, different studies have proposed that the ability of some
flavonoids to downregulate the altered immune response that occurs in intestinal inflammation may
be achieved through the inhibition of the TLR4/NF-κB signaling pathway, as it has been demonstrated
in vitro, when activated mouse macrophage J774 and RAW264.7 cells or human colonic HT-29 cells were
exposed to naringenin, kaempferol, quercetin, daidzein and cardamonin [71,75,99,100]. Similarly, it has
been reported that EGCG reduced LPS-induced TNFα production in macrophages (RAW264.7 cell line
and peritoneal macrophages) by blocking NF-κB activation. In the case of baicalin and cardamonin,
this effect was associated with the inhibition of NF-κB p65 subunit phosphorylation [40,83,101,102],
whereas quercetin was able to reduce the IκBα phosphorylation in LPS-activated BMDM [39]. The
flavonoids’ ability to interfere with NF-κB phosphorylation has been also demonstrated in IEC-6 cells
(an intestinal epithelial cell line), and in peripheral blood mononuclear cells (PBMC), Caco-2 and
BMDM cells. Specifically, baicalin, chrysin, quercetin, and EGCG administration showed inhibition of
the NF-κB pathway through other mechanisms [44,50,85,103,104].
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expression  [108,109].  The  binding  of  cytokines  to  their  corresponding  transmembrane  receptors 
induces  receptor  dimerization  of  its  subunits  and  association with  JAK  tyrosine  kinases.  Once 
activated,  STAT  proteins  dissociate  from  the  receptor,  homo‐  or  heterodimerize,  and  rapidly 
translocate  from  the  cytoplasm  into  the  nucleus. Thus,  the  JAK/STAT  cascade  provides  a direct 
mechanism to translate an extracellular signal into a transcriptional response [110] (Figure 7). Many 
Figure 6. P Kinase path ay. The itogen-activated protein kinase ( PK) cascades are signal
transduction pathways that involve a chain of three kinases activating each other in a series (MAPKKK,
MAPKK, and MAPK). The result of phosphorylation of various MAP kinase isoforms is the activation
of the three main MAP kinases: ERK (extracellular signal-related kinase), p38 MAPK, and JNK (c-Jun
NH2-terminal kinase). Cell division, migration, and survival generally involve ERK signaling. Cellular
stress activates the p38 MAPK and JNK pathways. The p38 MAPK pathway mediates transcription and
cell motility. JNK signaling regulates apoptosis and inflammation. Flavonoids’ immunomodulatory
properties may be related to a direct inhibitory effect on the kinases themselves or by modulation of
signal transduction events upstream of the relevant MAPK pathways.
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The MAPK signaling pathway also promotes immediate early gene and transcription factor
activation of cellular responses such as cytokine production, apoptosis and migration. A general
feature of MAPK pathways is the participation of a three-tiered kinase canonical cascade consisting
of a MAPK, a MAPK kinase (MAPKK) and a MAPK kinase kinase (MAPKKK) [105,106] (Figure 6).
Different in vitro studies have associated the flavonoid anti-inflammatory effect with a suppression
of this pathway; for instance, EGCG was able to suppress the maturation of murine dendritic cells
through the inhibition of extracellular signal-regulated kinase, p38 kinase and c-Jun NH2-terminal
kinase [107].
Finally, the JAK/STAT pathway transduces signals from a wide range of extracellular cytokine
stimuli to the nucleus in order to orchestrate an appropriate cellular response through target gene
expression [108,109]. The binding of cytokines to their corresponding transmembrane receptors induces
receptor dimerization of its subunits and association with JAK tyrosine kinases. Once activated, STAT
proteins dissociate from the receptor, homo- or heterodimerize, and rapidly translocate from the
cytoplasm into the nucleus. Thus, the JAK/STAT cascade provides a direct mechanism to translate an
extracellular signal into a transcriptional response [110] (Figure 7). Many flavonoids can inhibit both
JAK/STAT signaling, kaempferol and EGCG [49,75,111]. Interestingly, Western blotting analysis in
HT29 cells suggested that anthocyanin cyaniding-3-glucoside remarkably reduces cytokine-induced
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(J s) beco e activated and mediate phosphorylation f specific receptor tyrosine residues. This leads
to the recruitment of specific STATs (Signal Transducers and Activators of Transcription), which are
then also tyrosine-phosphorylated. Activated STATs are released from the receptor, they dimerize and
translocate to the nucleus to bind target genes associated with proliferation, differentiation and survival
of the cells, including immune cells. The inhibition of JAK-STAT signaling pathway by flavonoids
treatments leads to an immunomodulatory effect.
3.4. ffects of Flavonoids on Intestinal arrier Function
e o eostasis i t e astroi testi al tract is f ctio all ai tai e b a e it elial barrier,
co ose by a selective monocelular layer between the outside lumen and host tissues, which controls
the equilibrium between tolerance and immunity to microbes and non-self-a tigens. Several defects
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related to intestinal barrier function have been found in IBD patients. Whether mucosal barrier
impairment is a consequence of the inflammatory response or a primary defect that prompts mucosal
inflammation is still under debate [113]. However, transgenic animal models have clearly demonstrated
that a unique defect in the intestinal epithelial barrier is enough to trigger the development of chronic
gut inflammation [42]. In addition, several studies suggest that the impairment of the epithelial
barrier function can be considered as one of the early events that occur in intestinal inflammation,
since it facilitates the entry of antigens from the intestinal lumen to the mucosa that may prompt the
uncontrolled and exacerbated immune response [114,115]. For this reason, its recovery may contribute
to the beneficial effects produced by flavonoids in experimental colitis models. It has been reported
that different flavonoids such as quercitrin [36], rutin [63], hesperidin [116] and morin [53] improve
the colonic absorptive function greatly compromised in experimental colitis, leading to fewer diarrhea
symptoms, which are frequent in intestinal inflammation. The flavonoid anti-diarrheal effects have also
been related to their capacity to inhibit muscle contractility, enhance intestinal motility and reduce fluid
intraluminal accumulation in the gut lumen, as evidenced in different experimental studies [117–119].
Moreover, Azuma et al. (2013) [59] also reported that naringenin treatment in colitic mice resulted
in an improvement in the epithelial barrier permeability, through the preservation of the intestinal
tight junction barrier function and structure, which have been described to be compromised after DSS
administration [120,121]. In vitro studies have confirmed the ability of flavonoids, such as naringenin,
daidzenin and morin, to enhance epithelial barrier function. In particular, the incubation of these
flavanones with human intestinal Caco-2 epithelial cells resulted in an increased transepithelial
electrical resistance (TER) across the cell monolayers, which correlates to an improvement of tight
junction integrity [122]. This was confirmed by immunoblot analysis and confocal microscopy, which
demonstrated that naringenin, daidzenin and morin increase the cytoskeletal expression of the tight
junction proteins as well as their assembly, thus reinforcing epithelial integrity in this cell line [122].
In addition to a direct effect on tight protein function, indirect mechanisms can also account for the
beneficial effects of flavonoids in preserving the intestinal barrier function. In fact, it has been reported
that pro-inflammatory cytokines, such as IFNγ, TNFα or IL-6, can disrupt the epithelial barrier function
by apoptosis-independent mechanisms [43,123]. In consequence, the inhibitory effect exerted by these
compounds on the expression of IFNγ and IL-6 can also contribute to the improvement of the intestinal
permeability observed in DSS experimental colitis [59].
3.5. Interaction of Flavonoids with Gut Microbiota
As commented previously, there is increasing experimental evidence that supports the role of
luminal bacteria in the initiation and development of the intestinal inflammatory process, which
would be probably related to an imbalance in the intestinal microbiota composition, known as
dysbiosis [52,124]. In fact, previous studies have tried to explain the alterations that occur in the gut
microbiota or identify the bacterial populations that might be associated with the onset or recurrence
of IBD, thus promoting the access of potential pathogens to the lamina propria and triggering the
exacerbated immune response [3,125–128]. Different studies have reported that diets containing
bioactive compounds, such as phenolic compounds and tannins, can be considered as possible
complementary treatments for IBD due to their antimicrobial and antioxidant capacity [129]. Closely
related to this, it has been proposed that the impact of naringenin on microbiota composition can
also contribute to the beneficial effects exerted by this compound in intestinal inflammation. In this
sense, naringenin has been reported to inhibit both growth and adhesion of Salmonella typhimurium,
a Gram-negative pathogen, to cultured human Caco-2 cells [130]. On the contrary, the same study
revealed that this flavanone enhanced the proliferation and adhesion of the probiotic L. rhamnosus; of
note, this probiotic has been described to exert beneficial effects in human intestinal inflammation [131].
Moreover, it has also been reported that EGCG shows antimicrobial effects and capacity to disrupt
bacterial growth, which may also have a positive impact on colonic inflammation [56,132].
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4. Conclusions
The different studies performed with flavonoids focused on their intestinal anti-inflammatory
effect can definitively support their consideration as potential treatments for human IBD. In fact,
flavonoids have shown efficacy in experimental models and their mechanisms of action are similar
to those described for drugs currently used in human therapy [133]. Besides, their consumption in
edible vegetables from ancient times makes them a safe strategy. However, there is a clear demand for
clinical trials to confirm their actual role in the treatment of these intestinal inflammatory conditions.
Most of the studies carried out in humans consider the use of plants containing flavonoids, and they
have shown that these plants may induce clinical remission and clinical response in patients with
IBD, although more studies including larger number of patients are required to achieve more solid
conclusions [134]. Nevertheless, a pilot study has been carried out to evaluate the efficacy of the oral
administration of EGCG and has reported beneficial effects on UC patients refractory to 5-ASA and/or
azathioprine [135]. Further clinical studies should definitely be done to elucidate the efficacy and
safety of the different flavonoids in these intestinal inflammatory conditions and to finally consider
them as solid therapeutic strategies.
Acknowledgments: This work was supported by Junta de Andalucia (P10-AGR-6826 and CTS 164) and by the
Spanish Ministry of Economy and Competitiveness (AGL2015-67995-C3-3-R) with funds from the European Union.
Alba Rodriguez-Nogales is a postdoctoral fellow of University of Granada; Francesca Algieri is a postdoctoral
fellow of Junta de Andalucia; Maria Elena Rodriguez-Cabezas is a postdoctoral fellow of CIBER-EHD; Teresa Vezza
is a PhD student from the Postgraduate Program “Medicina Clinica y Salud Publica” at the University of Granada
(Spain). The CIBER-EHD is funded by the Instituto de Salud Carlos III.
Author Contributions: T.V., A. R.-N., F.A., M.P.U., M.E.R.-C. and J.G. contributed to design and write the
manuscript. F T.V., A. R.-N., F.A. prepared the table and figures.
Conflicts of Interest: The authors declare no conflict of interest.
Abbreviations
APCs, antigen-presenting cells; 5-ASA, aminosalicylic acid; BMDM, bone marrow-derived
macrophage; CAT, catalase; CD, Crohn’s disease; cNOS, constitutive nitric oxide; COX,
cyclooxygenase; C3G, cyanidin-3-glucoside; DC, dendritic cells; DSS, dextran sulphate sodium; EGCG,
epigallocatechin-3-gallate; GSH, glutathione; HETE, hydroxyeicosatetraenoic acid; IBD, inflammatory
bowel disease; ICAM, intercellular adhesion molecule; IL, interleukin; iNOS, inducible nitric oxide
synthase; KC, keratinocyte chemoattractant; LFA, lymphocyte function-associated antigen; LOX,
lipoxygenase; LPS, lipopolysaccharide; Mac-1; macrophage 1 antigen; MAPK, mitogen-activated
protein kinase; MCP, monocyte chemoattractant protein; MDA, malondialdehyde; MIP, macrophage
inflammatory proteins (MIP); MPO, myeloperoxidase; NADPH, nicotinamide adenine dinucleotide
phosphate; NF-κB, nuclear factor-κB; NK, natural killer cells; PLA2, cytoplasmatic phospholipase A2;
RNS, reactive nitrogen species; ROS, reactive oxygen species; SOD, superoxide dismutase; Th, T helper;
TLR, toll-like Receptor; TNBS, trinitrobenzene sulfonic acid; TNFα, tumour necrosis factor α; UC,
ulcerative colitis; VCAM, vascular cell adhesion molecule; VLA, very late antigen.
References
1. Baumgart, D.C.; Sandborn, W.J. Inflammatory bowel disease: Clinical aspects and established and evolving
therapies. Lancet 2007, 369, 1641–1657. [CrossRef]
2. Vucelic, B. Inflammatory bowel diseases: Controversies in the use of diagnostic procedures. Dig. Dis. 2009,
27, 269–277. [CrossRef] [PubMed]
3. Xavier, R.J.; Podolsky, D.K. Unravelling the pathogenesis of inflammatory bowel disease. Nature 2007, 448,
427–434. [CrossRef] [PubMed]
4. Fiocchi, C. Inflammatory bowel disease: Evolutionary concepts in biology, epidemiology, mechanisms and
therapy. Curr. Opin. Gastroenterol. 2013, 29, 347–349. [CrossRef] [PubMed]
Nutrients 2016, 8, 211 16 of 22
5. Kaser, A.; Zeissig, S.; Blumberg, R.S. Inflammatory bowel disease. Annu. Rev. Immunol. 2010, 28, 573–621.
[CrossRef] [PubMed]
6. Podolsky, D.K. Inflammatory bowel disease. N. Engl. J. Med. 2002, 347, 417–429. [CrossRef] [PubMed]
7. Sartor, R.B. Mechanisms of disease: Pathogenesis of crohn’s disease and ulcerative colitis. Nat. Clin. Pract.
Gastroenterol. Hepatol. 2006, 3, 390–407. [CrossRef] [PubMed]
8. Shih, D.Q.; Targan, S.R. Insights into IBD pathogenesis. Curr. Gastroenterol. Rep. 2009, 11, 473–480. [CrossRef]
[PubMed]
9. Strober, W.; Fuss, I.; Mannon, P. The fundamental basis of inflammatory bowel disease. J. Clin. Investig. 2007,
117, 514–521. [CrossRef] [PubMed]
10. Bernstein, C.N. Treatment of IBD: Where we are and where we are going. Am. J. Gastroenterol. 2015, 110,
114–126. [CrossRef] [PubMed]
11. Siegel, C.A. Review article: Explaining risks of inflammatory bowel disease therapy to patients. Aliment.
Pharmacol. Ther. 2011, 33, 23–32. [CrossRef] [PubMed]
12. Middleton, E., Jr.; Kandaswami, C.; Theoharides, T.C. The effects of plant flavonoids on mammalian cells:
Implications for inflammation, heart disease, and cancer. Pharmacol. Rev. 2000, 52, 673–751. [PubMed]
13. Mogensen, T.H. Pathogen recognition and inflammatory signaling in innate immune defenses. Clin. Microbiol.
Rev. 2009, 22, 240–273. [CrossRef] [PubMed]
14. Smith, P.D.; Smythies, L.E.; Shen, R.; Greenwell-Wild, T.; Gliozzi, M.; Wahl, S.M. Intestinal macrophages and
response to microbial encroachment. Mucosal Immunol. 2011, 4, 31–42. [CrossRef] [PubMed]
15. Cerovic, V.; Houston, S.A.; Scott, C.L.; Aumeunier, A.; Yrlid, U.; Mowat, A.M.; Milling, S.W. Intestinal
cd103(-) dendritic cells migrate in lymph and prime effector t cells. Mucosal Immunol. 2013, 6, 104–113.
[CrossRef] [PubMed]
16. Usui, T.; Preiss, J.C.; Kanno, Y.; Yao, Z.J.; Bream, J.H.; O’Shea, J.J.; Strober, W. T-bet regulates th1 responses
through essential effects on gata-3 function rather than on ifng gene acetylation and transcription. J. Exp. Med.
2006, 203, 755–766. [CrossRef] [PubMed]
17. Yang, X.O.; Panopoulos, A.D.; Nurieva, R.; Chang, S.H.; Wang, D.; Watowich, S.S.; Dong, C. Stat3 regulates
cytokine-mediated generation of inflammatory helper t cells. J. Biol. Chem. 2007, 282, 9358–9363. [CrossRef]
[PubMed]
18. Acosta-Rodriguez, E.V.; Napolitani, G.; Lanzavecchia, A.; Sallusto, F. Interleukins 1β and 6 but not
transforming growth factor-β are essential for the differentiation of interleukin 17-producing human T helper
cells. Nat. Immunol. 2007, 8, 942–949. [CrossRef] [PubMed]
19. Wilson, N.J.; Boniface, K.; Chan, J.R.; McKenzie, B.S.; Blumenschein, W.M.; Mattson, J.D.; Basham, B.;
Smith, K.; Chen, T.; Morel, F.; et al. Development, cytokine profile and function of human interleukin
17-producing helper t cells. Nat. Immunol. 2007, 8, 950–957. [CrossRef] [PubMed]
20. Romagnani, S. Lymphokine production by human t cells in disease states. Annu. Rev. Immunol. 1994, 12,
227–257. [CrossRef] [PubMed]
21. Korn, T.; Bettelli, E.; Oukka, M.; Kuchroo, V.K. Il-17 and th17 cells. Annu. Rev. Immunol. 2009, 27, 485–517.
[CrossRef] [PubMed]
22. Piechota-Polanczyk, A.; Fichna, J. Review article: The role of oxidative stress in pathogenesis and treatment
of inflammatory bowel diseases. Naunyn-Schmiedeberg’s Arch. Pharmacol. 2014, 387, 605–620. [CrossRef]
[PubMed]
23. Laing, K.J.; Secombes, C.J. Chemokines. Dev. Comp. Immunol. 2004, 28, 443–460. [CrossRef] [PubMed]
24. Vainer, B. Intercellular adhesion molecule-1 (icam-1) in ulcerative colitis: Presence, visualization, and
significance. APMIS Suppl. 2010, 118, 1–43. [CrossRef] [PubMed]
25. Sanchez-Munoz, F.; Dominguez-Lopez, A.; Yamamoto-Furusho, J.K. Role of cytokines in inflammatory
bowel disease. World J. Gastroenterol. 2008, 14, 4280–4288. [CrossRef] [PubMed]
26. Ahern, P.P.; Schiering, C.; Buonocore, S.; McGeachy, M.J.; Cua, D.J.; Maloy, K.J.; Powrie, F. Interleukin-23
drives intestinal inflammation through direct activity on T cells. Immunity 2010, 33, 279–288. [CrossRef]
[PubMed]
27. Maloy, K.J.; Kullberg, M.C. Il-23 and th17 cytokines in intestinal homeostasis. Mucosal Immunol. 2008, 1,
339–349. [CrossRef] [PubMed]
28. Kolls, J.K.; Linden, A. Interleukin-17 family members and inflammation. Immunity 2004, 21, 467–476.
[CrossRef] [PubMed]
Nutrients 2016, 8, 211 17 of 22
29. Park, H.; Li, Z.; Yang, X.O.; Chang, S.H.; Nurieva, R.; Wang, Y.H.; Wang, Y.; Hood, L.; Zhu, Z.; Tian, Q.; et al.
A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat. Immunol.
2005, 6, 1133–1141. [CrossRef] [PubMed]
30. Galvez, J. Role of Th17 cells in the pathogenesis of human IBD. ISRN Inflamm. 2014, 2014, 928461. [CrossRef]
[PubMed]
31. Izcue, A.; Coombes, J.L.; Powrie, F. Regulatory lymphocytes and intestinal inflammation. Annu. Rev.
Immunol. 2009, 27, 313–338. [CrossRef] [PubMed]
32. Li, M.O.; Flavell, R.A. Contextual regulation of inflammation: A duet by transforming growth factor-beta
and interleukin-10. Immunity 2008, 28, 468–476. [CrossRef] [PubMed]
33. Kim, H.P.; Son, K.H.; Chang, H.W.; Kang, S.S. Anti-inflammatory plant flavonoids and cellular action
mechanisms. J. Pharmacol. Sci. 2004, 96, 229–245. [CrossRef] [PubMed]
34. Perez-Cano, F.J.; Massot-Cladera, M.; Rodriguez-Lagunas, M.J.; Castell, M. Flavonoids affect host-microbiota
crosstalk through tlr modulation. Antioxidants 2014, 3, 649–670. [CrossRef] [PubMed]
35. Mizoguchi, A. Animal models of inflammatory bowel disease. Prog. Mol. Biol. Transl. Sci. 2012, 105, 263–320.
[PubMed]
36. Sanchez de Medina, F.; Galvez, J.; Romero, J.A.; Zarzuelo, A. Effect of quercitrin on acute and chronic
experimental colitis in the rat. J. Pharmacol. Exp. Ther. 1996, 278, 771–779. [PubMed]
37. Dubois, R.N.; Abramson, S.B.; Crofford, L.; Gupta, R.A.; Simon, L.S.; Van De Putte, L.B.; Lipsky, P.E.
Cyclooxygenase in biology and disease. FASEB J. 1998, 12, 1063–1073. [PubMed]
38. Castangia, I.; Nacher, A.; Caddeo, C.; Merino, V.; Diez-Sales, O.; Catalan-Latorre, A.; Fernandez-Busquets, X.;
Fadda, A.M.; Manconi, M. Therapeutic efficacy of quercetin enzyme-responsive nanovesicles for the
treatment of experimental colitis in rats. Acta Biomater. 2015, 13, 216–227. [CrossRef] [PubMed]
39. Comalada, M.; Camuesco, D.; Sierra, S.; Ballester, I.; Xaus, J.; Galvez, J.; Zarzuelo, A. In vivo quercitrin
anti-inflammatory effect involves release of quercetin, which inhibits inflammation through down-regulation
of the NF-κB pathway. Eur. J. Immunol. 2005, 35, 584–592. [CrossRef] [PubMed]
40. Ren, G.; Sun, A.; Deng, C.; Zhang, J.; Wu, X.; Wei, X.; Mani, S.; Dou, W.; Wang, Z. The anti-inflammatory effect
and potential mechanism of cardamonin in dss-induced colitis. Am. J. Physiol. Gastrointest. Liver Physiol.
2015, 309, G517–G527. [CrossRef] [PubMed]
41. Miller, M.J.; Sandoval, M. Nitric oxide. III. A molecular prelude to intestinal inflammation. Am. J. Physiol.
1999, 276, G795–G799. [PubMed]
42. Blumberg, R.S.; Saubermann, L.J.; Strober, W. Animal models of mucosal inflammation and their relation to
human inflammatory bowel disease. Curr. Opin. Immunol. 1999, 11, 648–656. [CrossRef]
43. Bruewer, M.; Luegering, A.; Kucharzik, T.; Parkos, C.A.; Madara, J.L.; Hopkins, A.M.; Nusrat, A.
Proinflammatory cytokines disrupt epithelial barrier function by apoptosis-independent mechanisms.
J. Immunol. 2003, 171, 6164–6172. [CrossRef] [PubMed]
44. Shin, E.K.; Kwon, H.S.; Kim, Y.H.; Shin, H.K.; Kim, J.K. Chrysin, a natural flavone, improves murine
inflammatory bowel diseases. Biochem. Biophys. Res. Commun. 2009, 381, 502–507. [CrossRef] [PubMed]
45. Melgarejo, E.; Medina, M.A.; Sanchez-Jimenez, F.; Urdiales, J.L. Targeting of histamine producing cells by
egcg: A green dart against inflammation? J. Physiol. Biochem. 2010, 66, 265–270. [CrossRef] [PubMed]
46. Bertran, X.; Mane, J.; Fernandez-Banares, F.; Castella, E.; Bartoli, R.; Ojanguren, I.; Esteve, M.; Gassull, M.A.
Intracolonic administration of zileuton, a selective 5-lipoxygenase inhibitor, accelerates healing in a rat
model of chronic colitis. Gut 1996, 38, 899–904. [CrossRef] [PubMed]
47. Korhonen, R.; Lahti, A.; Kankaanranta, H.; Moilanen, E. Nitric oxide production and signaling in
inflammation. Curr. Drug Targets Inflamm. Allergy 2005, 4, 471–479. [CrossRef] [PubMed]
48. Pavlick, K.P.; Laroux, F.S.; Fuseler, J.; Wolf, R.E.; Gray, L.; Hoffman, J.; Grisham, M.B. Role of reactive
metabolites of oxygen and nitrogen in inflammatory bowel disease. Free Radic. Biolo. Med. 2002, 33, 311–322.
[CrossRef]
49. Lee, I.T.; Lin, C.C.; Lee, C.Y.; Hsieh, P.W.; Yang, C.M. Protective effects of (´)-epigallocatechin-3-gallate
against TNF-α-induced lung inflammation via ROS-dependent ICAM-1 inhibition. J. Nutr. Biochem. 2013, 24,
124–136. [CrossRef] [PubMed]
50. Dou, W.; Zhang, J.; Zhang, E.; Sun, A.; Ding, L.; Chou, G.; Wang, Z.; Mani, S. Chrysin ameliorates chemically
induced colitis in the mouse through modulation of a PXR/NF-κB signaling pathway. J. Pharmacol. Exp. Ther.
2013, 345, 473–482. [CrossRef] [PubMed]
Nutrients 2016, 8, 211 18 of 22
51. Dou, W.; Zhang, J.; Ren, G.; Ding, L.; Sun, A.; Deng, C.; Wu, X.; Wei, X.; Mani, S.; Wang, Z. Mangiferin
attenuates the symptoms of dextran sulfate sodium-induced colitis in mice via NF-κB and MAPK signaling
inactivation. Int. Immunopharmacol. 2014, 23, 170–178. [CrossRef] [PubMed]
52. Fiocchi, C. Inflammatory bowel disease: Etiology and pathogenesis. Gastroenterology 1998, 115, 182–205.
[CrossRef]
53. Ocete, M.A.; Galvez, J.; Crespo, M.E.; Cruz, T.; Gonzalez, M.; Torres, M.I.; Zarzuelo, A. Effects of morin on
an experimental model of acute colitis in rats. Pharmacology 1998, 57, 261–270. [CrossRef] [PubMed]
54. Mariani, F.; Sena, P.; Roncucci, L. Inflammatory pathways in the early steps of colorectal cancer development.
World J. Gastroenterol. 2014, 20, 9716–9731. [CrossRef] [PubMed]
55. Bruckner, M.; Westphal, S.; Domschke, W.; Kucharzik, T.; Lugering, A. Green tea polyphenol
epigallocatechin-3-gallate shows therapeutic antioxidative effects in a murine model of colitis. J. Crohn’s
Colitis 2012, 6, 226–235. [CrossRef] [PubMed]
56. Oz, H.S.; Chen, T.; de Villiers, W.J. Green tea polyphenols and sulfasalazine have parallel anti-inflammatory
properties in colitis models. Front. Immunol. 2013, 4, 132. [CrossRef] [PubMed]
57. Kwon, H.S.; Oh, S.M.; Kim, J.K. Glabridin, a functional compound of liquorice, attenuates colonic
inflammation in mice with dextran sulphate sodium-induced colitis. Clin. Exp. Immunol. 2008, 151,
165–173. [CrossRef] [PubMed]
58. Kwon, K.H.; Murakami, A.; Tanaka, T.; Ohigashi, H. Dietary rutin, but not its aglycone quercetin, ameliorates
dextran sulfate sodium-induced experimental colitis in mice: Attenuation of pro-inflammatory gene
expression. Biochem. Pharmacol. 2005, 69, 395–406. [CrossRef] [PubMed]
59. Azuma, T.; Shigeshiro, M.; Kodama, M.; Tanabe, S.; Suzuki, T. Supplemental naringenin prevents intestinal
barrier defects and inflammation in colitic mice. J. Nutr. 2013, 143, 827–834. [CrossRef] [PubMed]
60. Camuesco, D.; Comalada, M.; Rodriguez-Cabezas, M.E.; Nieto, A.; Lorente, M.D.; Concha, A.; Zarzuelo, A.;
Galvez, J. The intestinal anti-inflammatory effect of quercitrin is associated with an inhibition in inos
expression. Br. J. Pharmacol. 2004, 143, 908–918. [CrossRef] [PubMed]
61. Sanchez de Medina, F.; Vera, B.; Galvez, J.; Zarzuelo, A. Effect of quercitrin on the early stages of hapten
induced colonic inflammation in the rat. Life Sci. 2002, 70, 3097–3108. [CrossRef]
62. Cruz, T.; Galvez, J.; Ocete, M.A.; Crespo, M.E.; Sanchez de Medina, L.H.F.; Zarzuelo, A. Oral administration
of rutoside can ameliorate inflammatory bowel disease in rats. Life Sci. 1998, 62, 687–695. [CrossRef]
63. Galvez, J.; Cruz, T.; Crespo, E.; Ocete, M.A.; Lorente, M.D.; Sanchez de Medina, F.; Zarzuelo, A. Rutoside as
mucosal protective in acetic acid-induced rat colitis. Planta Med. 1997, 63, 409–414. [CrossRef] [PubMed]
64. Rezaie, A.; Parker, R.D.; Abdollahi, M. Oxidative stress and pathogenesis of inflammatory bowel disease:
An epiphenomenon or the cause? Dig. Dis. Sci. 2007, 52, 2015–2021. [CrossRef] [PubMed]
65. Achitei, D.; Ciobica, A.; Balan, G.; Gologan, E.; Stanciu, C.; Stefanescu, G. Different profile of peripheral
antioxidant enzymes and lipid peroxidation in active and non-active inflammatory bowel disease patients.
Dig. Dis. Sci. 2013, 58, 1244–1249. [CrossRef] [PubMed]
66. Alzoghaibi, M.A. Concepts of oxidative stress and antioxidant defense in crohn’s disease.
World J. Gastroenterol. 2013, 19, 6540–6547. [CrossRef] [PubMed]
67. Veljaca, M.; Lesch, C.A.; Pllana, R.; Sanchez, B.; Chan, K.; Guglietta, A. BPC-15 reduces trinitrobenzene
sulfonic acid-induced colonic damage in rats. J. Pharmacol. Exp. Ther. 1995, 272, 417–422. [PubMed]
68. Seibel, J.; Molzberger, A.F.; Hertrampf, T.; Laudenbach-Leschowski, U.; Diel, P. Oral treatment with genistein
reduces the expression of molecular and biochemical markers of inflammation in a rat model of chronic
tnbs-induced colitis. Eur. J. Nutr. 2009, 48, 213–220. [CrossRef] [PubMed]
69. Al-Rejaie, S.S.; Abuohashish, H.M.; Al-Enazi, M.M.; Al-Assaf, A.H.; Parmar, M.Y.; Ahmed, M.M. Protective
effect of naringenin on acetic acid-induced ulcerative colitis in rats. World J. Gastroenterol. 2013, 19, 5633–5644.
[CrossRef] [PubMed]
70. Mascaraque, C.; Aranda, C.; Ocon, B.; Monte, M.J.; Suarez, M.D.; Zarzuelo, A.; Marin, J.J.;
Martinez-Augustin, O.; de Medina, F.S. Rutin has intestinal antiinflammatory effects in the CD4+ CD62L+
T cell transfer model of colitis. Pharmacol. Res. 2014, 90, 48–57. [CrossRef] [PubMed]
71. Dou, W.; Zhang, J.; Sun, A.; Zhang, E.; Ding, L.; Mukherjee, S.; Wei, X.; Chou, G.; Wang, Z.T.; Mani, S.
Protective effect of naringenin against experimental colitis via suppression of toll-like receptor 4/NF-κB
signalling. Br. J. Nutr. 2013, 110, 599–608. [CrossRef] [PubMed]
Nutrients 2016, 8, 211 19 of 22
72. Alderton, W.K.; Cooper, C.E.; Knowles, R.G. Nitric oxide synthases: Structure, function and inhibition.
Biochem. J. 2001, 357, 593–615. [CrossRef] [PubMed]
73. Sichel, G.; Corsaro, C.; Scalia, M.; Di Bilio, A.J.; Bonomo, R.P. In vitro scavenger activity of some flavonoids
and melanins against O2-dot. Free Radic. Biol. Med. 1991, 11, 1–8. [CrossRef]
74. Haenen, G.R.; Paquay, J.B.; Korthouwer, R.E.; Bast, A. Peroxynitrite scavenging by flavonoids.
Biochem. Biophys. Res. Commun. 1997, 236, 591–593. [CrossRef] [PubMed]
75. Hamalainen, M.; Nieminen, R.; Vuorela, P.; Heinonen, M.; Moilanen, E. Anti-inflammatory effects of
flavonoids: Genistein, kaempferol, quercetin, and daidzein inhibit stat-1 and NF-κB activations, whereas
flavone, isorhamnetin, naringenin, and pelargonidin inhibit only NF-κB activation along with their inhibitory
effect on inos expression and no production in activated macrophages. Mediat. Inflamm. 2007, 2007, 45673.
[CrossRef]
76. Kaufmann, H.J.; Taubin, H.L. Nonsteroidal anti-inflammatory drugs activate quiescent inflammatory bowel
disease. Ann. Intern. Med. 1987, 107, 513–516. [CrossRef] [PubMed]
77. Surh, Y.J.; Chun, K.S.; Cha, H.H.; Han, S.S.; Keum, Y.S.; Park, K.K.; Lee, S.S. Molecular mechanisms
underlying chemopreventive activities of anti-inflammatory phytochemicals: Down-regulation of cox-2 and
inos through suppression of NF-κB activation. Mutat. Res. 2001, 480–481, 243–268. [CrossRef]
78. Morita, I. Distinct functions of cox-1 and cox-2. Prostaglandins Other Lipid Mediat. 2002, 68–69, 165–175.
[CrossRef]
79. Willoughby, D.A.; Moore, A.R.; Colville-Nash, P.R. Cox-1, cox-2, and cox-3 and the future treatment of
chronic inflammatory disease. Lancet 2000, 355, 646–648. [CrossRef]
80. Serra, D.; Paixao, J.; Nunes, C.; Dinis, T.C.; Almeida, L.M. Cyanidin-3-glucoside suppresses cytokine-induced
inflammatory response in human intestinal cells: Comparison with 5-aminosalicylic acid. PLoS ONE 2013, 8,
e73001. [CrossRef] [PubMed]
81. Sharon, P.; Stenson, W.F. Enhanced synthesis of leukotriene b4 by colonic mucosa in inflammatory bowel
disease. Gastroenterology 1984, 86, 453–460. [PubMed]
82. Fretland, D.J.; Widomski, D.; Tsai, B.S.; Zemaitis, J.M.; Levin, S.; Djuric, S.W.; Shone, R.L.; Gaginella, T.S.
Effect of the leukotriene B4 receptor antagonist SC-41930 on colonic inflammation in rat, guinea pig and
rabbit. J. Pharmacol. Exp. Ther. 1990, 255, 572–576. [PubMed]
83. Cui, L.; Feng, L.; Zhang, Z.H.; Jia, X.B. The anti-inflammation effect of baicalin on experimental colitis
through inhibiting TLR4/NF-κB pathway activation. Int. Immunopharmacol. 2014, 23, 294–303. [CrossRef]
[PubMed]
84. Kwon, K.H.; Kim, K.I.; Jun, W.J.; Shin, D.H.; Cho, H.Y.; Hong, B.S. In vitro and in vivo effects of
macrophage-stimulatory polysaccharide from leaves of perilla frutescens var. Crispa. Biol. Pharm. Bull. 2002,
25, 367–371. [CrossRef] [PubMed]
85. Romier, B.; Van De Walle, J.; During, A.; Larondelle, Y.; Schneider, Y.J. Modulation of signalling nuclear
factor-κB activation pathway by polyphenols in human intestinal caco-2 cells. Br. J. Nutr. 2008, 100, 542–551.
[CrossRef] [PubMed]
86. Yamaji, O.; Nagaishi, T.; Totsuka, T.; Onizawa, M.; Suzuki, M.; Tsuge, N.; Hasegawa, A.; Okamoto, R.;
Tsuchiya, K.; Nakamura, T.; et al. The development of colitogenic CD4(+) T cells is regulated by il-7 in
collaboration with nk cell function in a murine model of colitis. J. Immunol. 2012, 188, 2524–2536. [CrossRef]
[PubMed]
87. Tao, F.; Qian, C.; Guo, W.; Luo, Q.; Xu, Q.; Sun, Y. Inhibition of Th1/Th17 responses via suppression of stat1
and stat3 activation contributes to the amelioration of murine experimental colitis by a natural flavonoid
glucoside icariin. Biochem. Pharmacol. 2013, 85, 798–807. [CrossRef] [PubMed]
88. Guan, S.; Fang, B.; Song, B.; Xiong, Y.; Lu, J. Immunosuppressive activity of alpinetin on activation and
cytokines secretion of murine t lymphocytes. Immunopharmacol. Immunotoxicol. 2014, 36, 290–296. [CrossRef]
[PubMed]
89. Song, B.; Guan, S.; Lu, J.; Chen, Z.; Huang, G.; Li, G.; Xiong, Y.; Zhang, S.; Yue, Z.; Deng, X. Suppressive
effects of fisetin on mice T lymphocytes in vitro and in vivo. J. Surg. Res. 2013, 185, 399–409. [CrossRef]
[PubMed]
90. Xu, J.; Yang, Y.; Qiu, G.; Lal, G.; Yin, N.; Wu, Z.; Bromberg, J.S.; Ding, Y. Stat4 is critical for the balance
between Th17 cells and regulatory T cells in colitis. J. Immunol. 2011, 186, 6597–6606. [CrossRef] [PubMed]
Nutrients 2016, 8, 211 20 of 22
91. Grip, O.; Janciauskiene, S.; Lindgren, S. Macrophages in inflammatory bowel disease. Curr. Drug Targets
Inflamm. Allergy 2003, 2, 155–160. [CrossRef] [PubMed]
92. Grisham, M.B.; Pavlick, K.P.; Laroux, F.S.; Hoffman, J.; Bharwani, S.; Wolf, R.E. Nitric oxide and chronic gut
inflammation: Controversies in inflammatory bowel disease. J. Investig. Med. 2002, 50, 272–283. [CrossRef]
[PubMed]
93. Comalada, M.; Ballester, I.; Bailon, E.; Sierra, S.; Xaus, J.; Galvez, J.; de Medina, F.S.; Zarzuelo, A. Inhibition
of pro-inflammatory markers in primary bone marrow-derived mouse macrophages by naturally occurring
flavonoids: Analysis of the structure-activity relationship. Biochem. Pharmacol. 2006, 72, 1010–1021.
[CrossRef] [PubMed]
94. Hoesel, B.; Schmid, J.A. The complexity of NF-κB signaling in inflammation and cancer. Mol. Cancer 2013,
12, 86. [CrossRef] [PubMed]
95. Pedersen, J.; Coskun, M.; Soendergaard, C.; Salem, M.; Nielsen, O.H. Inflammatory pathways of importance
for management of inflammatory bowel disease. World J. Gastroenterol. 2014, 20, 64–77. [CrossRef] [PubMed]
96. Coskun, M.; Salem, M.; Pedersen, J.; Nielsen, O.H. Involvement of JAK/STAT signaling in the pathogenesis
of inflammatory bowel disease. Pharmacol. Res. 2013, 76, 1–8. [CrossRef] [PubMed]
97. Roy, P.K.; Rashid, F.; Bragg, J.; Ibdah, J.A. Role of the JNK signal transduction pathway in inflammatory
bowel disease. World J. Gastroenterol. 2008, 14, 200–202. [CrossRef] [PubMed]
98. Niederberger, E.; Geisslinger, G. Proteomics and NF-κB: An update. Expert Rev. Proteom. 2013, 10, 189–204.
[CrossRef] [PubMed]
99. Dou, W.; Mukherjee, S.; Li, H.; Venkatesh, M.; Wang, H.; Kortagere, S.; Peleg, A.; Chilimuri, S.S.; Wang, Z.T.;
Feng, Y.; et al. Alleviation of gut inflammation by Cdx2/Pxr pathway in a mouse model of chemical colitis.
PLoS ONE 2012, 7, e36075. [CrossRef] [PubMed]
100. Vecchi Brumatti, L.; Marcuzzi, A.; Tricarico, P.M.; Zanin, V.; Girardelli, M.; Bianco, A.M. Curcumin and
inflammatory bowel disease: Potential and limits of innovative treatments. Molecules 2014, 19, 21127–21153.
[CrossRef] [PubMed]
101. Lin, Y.L.; Lin, J.K. (´)-epigallocatechin-3-gallate blocks the induction of nitric oxide synthase
by down-regulating lipopolysaccharide-induced activity of transcription factor nuclear factor-κB.
Mol. Pharmacol. 1997, 52, 465–472. [PubMed]
102. Yang, F.; de Villiers, W.J.; McClain, C.J.; Varilek, G.W. Green tea polyphenols block endotoxin-induced tumor
necrosis factor-production and lethality in a murine model. J. Nutr. 1998, 128, 2334–2340. [PubMed]
103. Yu, F.Y.; Huang, S.G.; Zhang, H.Y.; Ye, H.; Chi, H.G.; Zou, Y.; Lv, R.X.; Zheng, X.B. Effects of baicalin in CD4 +
CD29 + T cell subsets of ulcerative colitis patients. World J. Gastroenterol. 2014, 20, 15299–15309. [CrossRef]
[PubMed]
104. Yang, B.; Kotani, A.; Arai, K.; Kusu, F. Estimation of the antioxidant activities of flavonoids from their
oxidation potentials. Anal. Sci. 2001, 17, 599–604. [CrossRef] [PubMed]
105. Jeffrey, K.L.; Camps, M.; Rommel, C.; Mackay, C.R. Targeting dual-specificity phosphatases: Manipulating
map kinase signalling and immune responses. Nat. Rev. Drug Discov. 2007, 6, 391–403. [CrossRef] [PubMed]
106. Broom, O.J.; Massoumi, R.; Sjolander, A. Alpha2beta1 integrin signalling enhances cyclooxygenase-2
expression in intestinal epithelial cells. J. Cell. Physiol. 2006, 209, 950–958. [CrossRef] [PubMed]
107. Ahn, M.R.; Kumazawa, S.; Hamasaka, T.; Bang, K.S.; Nakayama, T. Antioxidant activity and constituents of
propolis collected in various areas of korea. J. Agric. Food Chem. 2004, 52, 7286–7292. [CrossRef] [PubMed]
108. Stark, G.R.; Darnell, J.E., Jr. The JAK-STAT pathway at twenty. Immunity 2012, 36, 503–514. [CrossRef]
[PubMed]
109. O’Shea, N.; Arendt, E.K.; Gallaghera, E. Dietary fibre and phytochemical characteristics of fruit
and vegetable by-products and their recent applications as novel ingredients in food products.
Innov. Food Sci. Emerg. Technol. 2012, 16, 1–10. [CrossRef]
110. Levy, D.E.; Darnell, J.E., Jr. Stats: Transcriptional control and biological impact. Nat. Rev. Mol. Cell Biol. 2002,
3, 651–662. [CrossRef] [PubMed]
111. Liu, S.; Li, D.; Huang, B.; Chen, Y.; Lu, X.; Wang, Y. Inhibition of pancreatic lipase, alpha-glucosidase,
alpha-amylase, and hypolipidemic effects of the total flavonoids from nelumbo nucifera leaves.
J. Ethnopharmacol. 2013, 149, 263–269. [CrossRef] [PubMed]
Nutrients 2016, 8, 211 21 of 22
112. Schreiber, S.; Rosenstiel, P.; Hampe, J.; Nikolaus, S.; Groessner, B.; Schottelius, A.; Kuhbacher, T.; Hamling, J.;
Folsch, U.R.; Seegert, D. Activation of signal transducer and activator of transcription (stat) 1 in human
chronic inflammatory bowel disease. Gut 2002, 51, 379–385. [CrossRef] [PubMed]
113. Teshima, C.W.; Dieleman, L.A.; Meddings, J.B. Abnormal intestinal permeability in crohn’s disease
pathogenesis. Ann. N. Y. Acad. Sci. 2012, 1258, 159–165. [CrossRef] [PubMed]
114. Mankertz, J.; Schulzke, J.D. Altered permeability in inflammatory bowel disease: Pathophysiology and
clinical implications. Curr. Opin. Gastroenterol. 2007, 23, 379–383. [CrossRef] [PubMed]
115. Vivinus-Nebot, M.; Frin-Mathy, G.; Bzioueche, H.; Dainese, R.; Bernard, G.; Anty, R.; Filippi, J.;
Saint-Paul, M.C.; Tulic, M.K.; Verhasselt, V.; et al. Functional bowel symptoms in quiescent inflammatory
bowel diseases: Role of epithelial barrier disruption and low-grade inflammation. Gut 2014, 63, 744–752.
[CrossRef] [PubMed]
116. Crespo, M.E.; Galvez, J.; Cruz, T.; Ocete, M.A.; Zarzuelo, A. Anti-inflammatory activity of diosmin and
hesperidin in rat colitis induced by tnbs. Planta Med. 1999, 65, 651–653. [CrossRef] [PubMed]
117. Di Carlo, G.; Autore, G.; Izzo, A.A.; Maiolino, P.; Mascolo, N.; Viola, P.; Diurno, M.V.; Capasso, F. Inhibition
of intestinal motility and secretion by flavonoids in mice and rats: Structure-activity relationships. J. Pharm.
Pharmacol. 1993, 45, 1054–1059. [CrossRef] [PubMed]
118. Galvez, J.; Duarte, J.; Sanchez de Medina, F.; Jiménez, J.; Zarzuelo, A. Inhibitory effects of quercetin on
guinea-pig ileum contractions. Phytother. Res. PTR 1996, 10, 66–69. [CrossRef]
119. Meli, R.; Autore, G.; Di Carlo, G.; Capasso, F.I. Inhibitory action of quercetin on itestinal transit time.
Phytother. Res. PTR 1990, 4, 201–202. [CrossRef]
120. Kong, J.; Zhang, Z.; Musch, M.W.; Ning, G.; Sun, J.; Hart, J.; Bissonnette, M.; Li, Y.C. Novel role of the
vitamin d receptor in maintaining the integrity of the intestinal mucosal barrier. Am. J. Physiol. Gastrointest.
Liver Physiol. 2008, 294, G208–G216. [CrossRef] [PubMed]
121. Iwaya, H.; Maeta, K.; Hara, H.; Ishizuka, S. Mucosal permeability is an intrinsic factor in susceptibility to
dextran sulfate sodium-induced colitis in rats. Exp. Biol. Med. 2012, 237, 451–460. [CrossRef] [PubMed]
122. Noda, S.; Tanabe, S.; Suzuki, T. Differential effects of flavonoids on barrier integrity in human intestinal
caco-2 cells. J. Agric. Food Chem. 2012, 60, 4628–4633. [CrossRef] [PubMed]
123. Suzuki, T.; Yoshinaga, N.; Tanabe, S. Interleukin-6 (il-6) regulates claudin-2 expression and tight junction
permeability in intestinal epithelium. J. Biol. Chem. 2011, 286, 31263–31271. [CrossRef] [PubMed]
124. Geier, M.S.; Butler, R.N.; Howarth, G.S. Inflammatory bowel disease: Current insights into pathogenesis
and new therapeutic options; probiotics, prebiotics and synbiotics. Int. J. Food Microbiol. 2007, 115, 1–11.
[CrossRef] [PubMed]
125. Bellaguarda, E.; Chang, E.B. IBD and the gut microbiota—From bench to personalized medicine.
Curr. Gastroenterol. Rep. 2015, 17, 15. [CrossRef] [PubMed]
126. Elson, C.O.; Cong, Y.; McCracken, V.J.; Dimmitt, R.A.; Lorenz, R.G.; Weaver, C.T. Experimental models of
inflammatory bowel disease reveal innate, adaptive, and regulatory mechanisms of host dialogue with the
microbiota. Immunol. Rev. 2005, 206, 260–276. [CrossRef] [PubMed]
127. Swidsinski, A.; Weber, J.; Loening-Baucke, V.; Hale, L.P.; Lochs, H. Spatial organization and composition
of the mucosal flora in patients with inflammatory bowel disease. J. Clin. Microbiol. 2005, 43, 3380–3389.
[CrossRef] [PubMed]
128. Loftus, E.V., Jr. Management of extraintestinal manifestations and other complications of inflammatory
bowel disease. Curr. Gastroenterol. Rep. 2004, 6, 506–513. [CrossRef] [PubMed]
129. Larrosa, M.; Luceri, C.; Vivoli, E.; Pagliuca, C.; Lodovici, M.; Moneti, G.; Dolara, P. Polyphenol metabolites
from colonic microbiota exert anti-inflammatory activity on different inflammation models. Mol. Nutr.
Food Res. 2009, 53, 1044–1054. [CrossRef] [PubMed]
130. Parkar, S.G.; Stevenson, D.E.; Skinner, M.A. The potential influence of fruit polyphenols on colonic microflora
and human gut health. Int. J. Food Microbiol. 2008, 124, 295–298. [CrossRef] [PubMed]
131. Ghouri, Y.A.; Richards, D.M.; Rahimi, E.F.; Krill, J.T.; Jelinek, K.A.; DuPont, A.W. Systematic review
of randomized controlled trials of probiotics, prebiotics, and synbiotics in inflammatory bowel disease.
Clin. Exp. Gastroenterol. 2014, 7, 473–487. [PubMed]
132. Steinmann, J.; Buer, J.; Pietschmann, T.; Steinmann, E. Anti-infective properties of epigallocatechin-3-gallate
(EGCG), a component of green tea. Br. J. Pharmacol. 2013, 168, 1059–1073. [CrossRef] [PubMed]
Nutrients 2016, 8, 211 22 of 22
133. Valatas, V.; Vakas, M.; Kolios, G. The value of experimental models of colitis in predicting efficacy of
biological therapies for inflammatory bowel diseases. Am. J. Physiol. Gastrointest. Liver Physiol. 2013, 305,
G763–G785. [CrossRef] [PubMed]
134. Algieri, F.; Rodriguez-Nogales, A.; Rodriguez-Cabezas, M.E.; Risco, S.; Ocete, M.A.; Galvez, J. Botanical
drugs as an emerging strategy in inflammatory bowel disease: A review. Mediat. Inflamm. 2015, 2015, 179616.
[CrossRef] [PubMed]
135. Dryden, G.W.; Lam, A.; Beatty, K.; Qazzaz, H.H.; McClain, C.J. A pilot study to evaluate the safety and
efficacy of an oral dose of (´)-epigallocatechin-3-gallate-rich polyphenon e in patients with mild to moderate
ulcerative colitis. Inflamm. Bowel Dis. 2013, 19, 1904–1912. [CrossRef] [PubMed]
© 2016 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC-BY) license (http://creativecommons.org/licenses/by/4.0/).
